Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Observational Study of Tasfygo Tablet 35 mg to Evaluate the Safety of Tasfygo in Patients With Unresectable Biliary Tract Cancer With FGFR2 Fusion Gene Positivity Who Progressed After Chemotherapy

NCT06793709 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.

NCT NCT06793709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06793709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Observational Study of Tasfygo Tablet 35 mg to Evaluate the Safety of Tasfygo in Patients With Unresectable Biliary Tract Cancer With FGFR2 Fusion Gene Positivity Who Progressed After Chemotherapy
Lead sponsor
Eisai Co., Ltd.
Phase
Observational
Overall status
Recruiting
Start date
July 10, 2025
Completion date
November 20, 2032
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer